PCSA
Processa Pharmaceuticals, Inc.Company Information
- Company Name
- Processa Pharmaceuticals, Inc.
- CIK
- CIK0001533743
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PCSA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PCSA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-01
- Last sale
- —
- Shares purchased (TTM)
- 80,731
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 255,549
- Shares outstanding
- 2,750,742
- Ownership
- 9.29%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -15.23%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 2 | 6 | 6 | 7 | 3 | 1 | 3 | 6 | 9 | 5 | 7 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 2 | 2 | 6 | 7 | 7 | 4 | 2 | 5 | 7 | 10 | 6 | 8 | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | ||||||
| Crypto Asset Fair Value Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Other Assets Noncurrent | ||||||||||||||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | - | - | - | - | - | - | 1 | - | - | - | - | - | ||||||
| Crypto Asset Fair Value | 0 | 2 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Security Deposit | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Assets | 2 | 5 | 8 | 8 | 8 | 5 | 3 | 5 | 8 | 10 | 6 | 8 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Operating Lease Right Of Use Asset | - | - | - | - | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
Other Assets | ||||||||||||||||||
| Other Assets | - | - | - | - | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | ||||||
| Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Accounts Payable Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | ||||||
| Liabilities | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 107 | 107 | 107 | 104 | 100 | 94 | 89 | 89 | 87 | 87 | 81 | 80 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -0 | 3 | 6 | 6 | 6 | 4 | 2 | 4 | 6 | 9 | 5 | 7 | ||||||
| Treasury Stock Value | - | - | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -107 | -104 | -101 | -97 | -94 | -90 | -87 | -84 | -81 | -78 | -75 | -73 | ||||||
| Liabilities And Stockholders Equity | 2 | 5 | 8 | 8 | 8 | 5 | 3 | 5 | 8 | 10 | 6 | 8 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | 1 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 3 | 3 | 57 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 3 | 3 | 57 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProcessa Pharmaceuticals, Inc. (PCSA) — SEC Financial Statements & Analysis
Processa Pharmaceuticals, Inc. (PCSA) is a pharmaceutical preparations company, incorporated in DE. Processa Pharmaceuticals, Inc. trades on Nasdaq as: PCSA. Processa Pharmaceuticals, Inc. (PCSA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Processa Pharmaceuticals, Inc. carries a market cap of $5.28M, a P/E ratio of -0.39x, a P/B ratio of -16.64x, an enterprise value of $5.09M, and an EV/EBITDA multiple of -0.40x. On profitability, it posts a Return on Equity (ROE) of -464.20%, a Return on Assets (ROA) of -262.17%, and a Return on Invested Capital (ROIC) of -1956.60%. Per share, it reports EPS of $-4.89, diluted EPS of $-4.89, free cash flow per share of $-4.35, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 4.32% year-over-year and EPS growth of -76.15% year-over-year. On the balance sheet, it maintains a current ratio of 0.87x, a quick ratio of 0.28x, working capital of $-320.55K, a debt-to-equity ratio of -7.52x, a debt ratio of 1.15, an interest coverage ratio of -6419.41x, free cash flow of $-11.97M (TTM), and net debt of $-196.32K. Figures sourced from SEC EDGAR.
- Market Cap
- $5.28M
- P/E TTM
- -0.39x
- EPS TTM
- $-4.89
- P/B TTM
- -16.64x
- ROE TTM
- -464.20%
- ROA TTM
- -262.17%
- Debt To Equity
- -7.52x
- Free Cash Flow TTM
- $-11.97M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Processa Pharmaceuticals, Inc. in?
Processa Pharmaceuticals, Inc. (PCSA) operates in the Pharmaceutical Preparations industry.
What exchange does PCSA trade on?
Processa Pharmaceuticals, Inc. (PCSA) trades on the Nasdaq.
Where is Processa Pharmaceuticals, Inc. incorporated?
Processa Pharmaceuticals, Inc. is incorporated in DE.
When was Processa Pharmaceuticals, Inc. (PCSA)'s most recent SEC filing?
Processa Pharmaceuticals, Inc. (PCSA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is PCSA's market cap?
Processa Pharmaceuticals, Inc. (PCSA) has a market capitalization of $5.28M as of 2026-06-30.
What is PCSA's EPS (earnings per share)?
Processa Pharmaceuticals, Inc. (PCSA)'s trailing twelve month EPS is $-4.89 as of 2026-06-30.
What is PCSA's ROE (return on equity)?
Processa Pharmaceuticals, Inc. (PCSA)'s trailing twelve month Return on Equity (ROE) is -464.20% as of 2026-06-30.
What is PCSA's ROA (return on assets)?
Processa Pharmaceuticals, Inc. (PCSA)'s trailing twelve month Return on Assets (ROA) is -262.17% as of 2026-06-30.
What is PCSA's ROIC (return on invested capital)?
Processa Pharmaceuticals, Inc. (PCSA)'s trailing twelve month Return on Invested Capital (ROIC) is -1956.60% as of 2026-03-31.
What is PCSA's EV/EBITDA?
Processa Pharmaceuticals, Inc. (PCSA)'s trailing twelve month EV/EBITDA is -0.40x as of 2026-06-30.